Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Rein Therapeutics (RNTX) Return on Equity (2017 - 2025)

Rein Therapeutics filings provide 9 years of Return on Equity readings, the most recent being 0.34% for Q4 2025.

  • For the quarter ending Q4 2025, Return on Equity fell 16.0% year-over-year to 0.34%, compared with a TTM value of 0.34% through Dec 2025, down 16.0%, and an annual FY2025 reading of 0.28%, down 10.0% over the prior year.
  • Return on Equity hit 0.34% in Q4 2025 for Rein Therapeutics, down from 0.19% in the prior quarter.
  • The five-year high for Return on Equity was 0.18% in Q4 2024, with the low at 1.46% in Q1 2023.
  • Median Return on Equity over the past 5 years was 0.41% (2021), compared with a mean of 0.61%.
  • The sharpest move saw Return on Equity surged 169bps in 2021, then plummeted -76bps in 2022.
  • Year by year, Return on Equity stood at 0.56% in 2021, then plummeted by -135bps to 1.33% in 2022, then skyrocketed by 78bps to 0.29% in 2023, then surged by 38bps to 0.18% in 2024, then plummeted by -87bps to 0.34% in 2025.
  • According to Business Quant data, Return on Equity over the past three periods came in at 0.34%, 0.19%, and 0.2% for Q4 2025, Q3 2025, and Q2 2025 respectively.